Kwang‐Su Park

3.2k total citations · 1 hit paper
89 papers, 2.4k citations indexed

About

Kwang‐Su Park is a scholar working on Molecular Biology, Oncology and Pharmacology. According to data from OpenAlex, Kwang‐Su Park has authored 89 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 40 papers in Molecular Biology, 14 papers in Oncology and 9 papers in Pharmacology. Recurrent topics in Kwang‐Su Park's work include Protein Degradation and Inhibitors (16 papers), Ubiquitin and proteasome pathways (11 papers) and Peptidase Inhibition and Analysis (7 papers). Kwang‐Su Park is often cited by papers focused on Protein Degradation and Inhibitors (16 papers), Ubiquitin and proteasome pathways (11 papers) and Peptidase Inhibition and Analysis (7 papers). Kwang‐Su Park collaborates with scholars based in South Korea, United States and Japan. Kwang‐Su Park's co-authors include Jian Jin, Youhoon Chong, H. Ümit Kanıskan, Brandon Dale, Yue Xiong, Meng Cheng, Hyunah Choo, Mi Kyoung Kim, Mi Kyoung Kim and Gang Greg Wang and has published in prestigious journals such as Journal of the American Chemical Society, Nucleic Acids Research and Nature reviews. Cancer.

In The Last Decade

Kwang‐Su Park

85 papers receiving 2.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Advancing targeted protein degradation for cancer therapy

2021 425 citations Brandon Dale, Meng Cheng et al. Nature reviews. Cancer profile →

Peers

Kwang‐Su Park

ONCOL

HEMAT

PHARM

Ján Sedlák Slovakia

Yuqing Yang China

Jan Kovář Czechia

Zhengping Wang China

Dennis M. Miller United States

Anuraj Nayarisseri India

Masahiro Takada Japan

Hanchun Chen China

Xin Xu United States

Ján Sedlák Slovakia

Kwang‐Su Park

919 ×0.6

333 ×0.8

ONCOL

175 ×0.9

141 ×0.8

HEMAT

55 ×0.5

PHARM

Citations per year, relative to Kwang‐Su Park Kwang‐Su Park (= 1×) peers Ján Sedlák

Countries citing papers authored by Kwang‐Su Park

Since Specialization

Citations

This map shows the geographic impact of Kwang‐Su Park's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kwang‐Su Park with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kwang‐Su Park more than expected).

Fields of papers citing papers by Kwang‐Su Park

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kwang‐Su Park. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kwang‐Su Park. The network helps show where Kwang‐Su Park may publish in the future.

Co-authorship network of co-authors of Kwang‐Su Park

This figure shows the co-authorship network connecting the top 25 collaborators of Kwang‐Su Park. A scholar is included among the top collaborators of Kwang‐Su Park based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kwang‐Su Park. Kwang‐Su Park is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yoo, Seungyeul, Feng Jiang, Eric Park, et al.. (2025). Epigenomic analysis identifies DTP subpopulation using HOPX to develop targeted therapy resistance in lung adenocarcinoma. iScience. 28(5). 112387–112387.

Park, Kwang‐Su & Minji Jeon. (2025). Advancing PROTAC Discovery Through Artificial Intelligence: Opportunities, Challenges, and Future Directions. Pharmaceuticals. 18(12). 1793–1793.

Xiong, Yan, Holger Greschik, C. Johansson, et al.. (2024). Discovery of a Potent, Selective, and Cell-Active SPIN1 Inhibitor. Journal of Medicinal Chemistry. 67(7). 5837–5853. 2 indexed citations

Wang, Jun, Kwang‐Su Park, Xufen Yu, et al.. (2022). A cryptic transactivation domain of EZH2 binds AR and AR’s splice variant, promoting oncogene activation and tumorous transformation. Nucleic Acids Research. 50(19). 10929–10946. 26 indexed citations

Meng, Fanye, Chenxi Xu, Kwang‐Su Park, et al.. (2022). Discovery of a First-in-Class Degrader for Nuclear Receptor Binding SET Domain Protein 2 (NSD2) and Ikaros/Aiolos. Journal of Medicinal Chemistry. 65(15). 10611–10625. 39 indexed citations

Dale, Brandon, Kwang‐Su Park, H. Ümit Kanıskan, et al.. (2022). Targeting Triple-Negative Breast Cancer by a Novel Proteolysis Targeting Chimera Degrader of Enhancer of Zeste Homolog 2. ACS Pharmacology & Translational Science. 5(7). 491–507. 32 indexed citations

Meng, Fanye, Kwang‐Su Park, Li Wang, et al.. (2021). Harnessing the E3 Ligase KEAP1 for Targeted Protein Degradation. Journal of the American Chemical Society. 143(37). 15073–15083. 96 indexed citations

Yu, Xufen, Jithesh Kottur, Yudao Shen, et al.. (2021). A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models. Science Translational Medicine. 13(613). eabj1578–eabj1578. 91 indexed citations

Dale, Brandon, Meng Cheng, Kwang‐Su Park, et al.. (2021). Advancing targeted protein degradation for cancer therapy. Nature reviews. Cancer. 21(10). 638–654. 425 indexed citations breakdown →

10.

Park, Kwang‐Su, et al.. (2020). A contamination analysis of the primary coolant system with Monte Carlo simulations. Annals of Nuclear Energy. 142. 107386–107386. 3 indexed citations

11.

Park, Kwang‐Su, et al.. (2019). Characterization of contribution of vehicle emissions to ambient NO 2 using stable isotopes. Analytical Science and Technology. 32(1). 17–23. 2 indexed citations

12.

Kim, So Yeon, Hye Rin Lee, Kwang‐Su Park, Bong‐Gyu Kim, & Joong‐Hoon Ahn. (2014). Metabolic engineering of Escherichia coli for the biosynthesis of flavonoid-O-glucuronides and flavonoid-O-galactoside. Applied Microbiology and Biotechnology. 99(5). 2233–2242. 46 indexed citations

13.

Sugiyama, Akihiko, Ryoji Miyahara, & Kwang‐Su Park. (2013). A-4-6 IMPACT-NOISE SUPPRESSION WITH PHASE-BASED DETECTION. European Signal Processing Conference. 2013. 1–5. 1 indexed citations

14.

Choi, Kyoung-Ho, et al.. (2013). Physicochemical characteristics and electric conductivity of various fruit wines.. International Food Research Journal. 20(6). 2987–2993. 12 indexed citations

15.

Rodríguez-Marek, Adrián, James A. Bay, Kwang‐Su Park, et al.. (2010). Engineering Analysis of Ground Motion Records from the 2001 M _w 8.4 Southern Peru Earthquake. Earthquake Spectra. 26(2). 499–524. 8 indexed citations

16.

Park, Kwang‐Su, et al.. (2010). 3-O-Arylmethylgalangin, a novel isostere for anti-HCV 1,3-diketoacids (DKAs). Bioorganic & Medicinal Chemistry. 18(21). 7331–7337. 6 indexed citations

17.

Park, Kwang‐Su, et al.. (2010). 7-O-Arylmethylgalangin as a novel scaffold for anti-HCV agents. Bioorganic & Medicinal Chemistry Letters. 20(19). 5709–5712. 12 indexed citations

18.

Kim, Jinyoung, Ki-Sun Kim, Kwang‐Su Park, et al.. (2008). Effects of the aryl linker and the aromatic substituent on the anti-HCV activities of aryl diketoacid (ADK) analogues. Bioorganic & Medicinal Chemistry Letters. 18(16). 4661–4665. 14 indexed citations

19.

Kim, Jin‐Young, et al.. (2006). S-adenosyl-L-methionine analogues to enhance the production of actinorhodin. Journal of Microbiology and Biotechnology. 16(7). 1154–1157. 2 indexed citations

20.

Park, Kwang‐Su, Chi‐Hyuck Jun, & Sooyoung Kim. (1997). The Comparison and Use of Yield Models in Semiconductor Manufacturing. IE interfaces. 10(1). 79–93. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact